PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers
Luis Martí‐Bonmatí, Ángel Alberich‐Bayarri, Ruth Ladenstein, Ignácio Blanquer, J. Damián Segrelles, Leonor Cerdá-Alberich, Polyxeni Gkontra, Barbara Hero, José Manuel García‐Aznar, Daniel A. Keim, Wolfgang Jentner, Karine Seymour, Ana Jiménez-Pastor, Ismael González‐Valverde, Blanca Martínez de las Heras, Samira Essiaf, Dawn Walker, Michel Rochette, Marian Bubak, Jordi Mestres, Marco Viceconti, Gracia Martí-Besa, Adela Cañete, Paul Richmond, Kenneth Y. Wertheim, Tomasz Gubała, Marek Kasztelnik, Jan Meizner, Piotr Nowakowski, Salvador Gilpérez, A. Suárez‐García, Mario Aznar, Giuliana Restante, Emanuele Neri
Abstract
PRIMAGE is one of the largest and more ambitious research projects dealing with medical imaging, artificial intelligence and cancer treatment in children. It is a 4-year European Commission-financed project that has 16 European partners in the consortium, including the European Society for Paediatric Oncology, two imaging biobanks, and three prominent European paediatric oncology units. The project is constructed as an observational in silico study involving high-quality anonymised datasets (imaging, clinical, molecular, and genetics) for the training and validation of machine learning and multiscale algorithms. The open cloud-based platform will offer precise clinical assistance for phenotyping (diagnosis), treatment allocation (prediction), and patient endpoints (prognosis), based on the use of imaging biomarkers, tumour growth simulation, advanced visualisation of confidence scores, and machine-learning approaches. The decision support prototype will be constructed and validated on two paediatric cancers: neuroblastoma and diffuse intrinsic pontine glioma. External validation will be performed on data recruited from independent collaborative centres. Final results will be available for the scientific community at the end of the project, and ready for translation to other malignant solid tumours.